Search research articles
Contact Us
Filters
Showing results (271-280 of 282) with videos related to
Page
of 29
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
S Loibl, M Untch, N Burchardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1997
Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease
M Loeffler, V Diehl, M Pfreundschuh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 1999
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group
V Diehl, J Franklin, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 1998
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group
V Diehl, J Franklin, D Hasenclever, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2013
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Chao Zhang, Prabha N Ibrahim, Jiazhong Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2004
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial
M Sieber, H Tesch, B Pfistner, et al.
ESMO Open
|
May 16, 2022
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force
E Razis, M J Escudero, C Palmieri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study
N Nabieva, T Fehm, L Häberle, et al.
Geburtshilfe Und Frauenheilkunde
|
January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study
P A Fasching, T Fehm, S Kellner, et al.
Page
of 29
Search research articles
Search
Showing results (271-280 of 282) with videos related to
Sort By:
Page
of 29
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
S Loibl, M Untch, N Burchardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1997
Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease
M Loeffler, V Diehl, M Pfreundschuh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 1999
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group
V Diehl, J Franklin, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 1998
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group
V Diehl, J Franklin, D Hasenclever, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2013
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Chao Zhang, Prabha N Ibrahim, Jiazhong Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2004
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial
M Sieber, H Tesch, B Pfistner, et al.
ESMO Open
|
May 16, 2022
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force
E Razis, M J Escudero, C Palmieri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study
N Nabieva, T Fehm, L Häberle, et al.
Geburtshilfe Und Frauenheilkunde
|
January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study
P A Fasching, T Fehm, S Kellner, et al.
Page
of 29